<DOC>
	<DOCNO>NCT03068234</DOCNO>
	<brief_summary>This study evaluate efficacy safety antifibrotic agent , pirfenidone treatment systemic sclerosis . The primary outcome study improvement skin fibrosis .</brief_summary>
	<brief_title>Pirfenidone Treatment Skin Fibrosis Systemic Sclerosis</brief_title>
	<detailed_description>All patient enrol suffer moderate severe skin fibrosis screen stage . The study period 52 week . The study contain two stage , 24-week blind stage follow open stage another 24-week period time . Subjects receive pirfenidone placebo randomize first 24-week receive pirfenidone treatment second 24-week , combination low dose steroid . The secondary outcome study include limit safety , improvement lung fibrosis digital ulcer burden .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>Fulfill EULAR/ACR classification criterion ( 2013 ) systemic sclerosis ( SSc ) . Subjects must mRSS≥10 screen stage Subjects must sign fibrosis chest CT screening stage If subject receive treatment , stable least 3 month screen significant efficacy ( ΔmRSS≤2 ) Subjects connective tissue disease overlap SSc Subjects skin atrophy main cutaneous manifestation Subjects active digital ulcer gangrene Active severe SScdriven renal disease heart dysfunction screen Subjects significant hematologic abnormality Abnormal liver function test screening ( ALT , AST total bilirubin 2 fold upper normal level Clinically significant active infection include ongoing chronic infection History human immunodeficiency virus ( HIV ) Confirmed Positive test hepatitis B positive test hepatitis C Active tuberculosis Live attenuate vaccine within 4 week prior screen Subjects significant hematologic abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>